DAY 2: GLP-1 Receptor Agonists and IBD Outcomes

Aun Muhammad, MD, from University of Mississippi Medical Center, conducted a retrospective cohort study using data from the TriNetX database, on 5,162 patients with BMI ≥30 kg/m2 and a diagnosis of IBD who received either semaglutide or dulaglutide GLP-1 receptor agonists at any time after diagnosis. Semaglutide use was associated with a lower 3-, 5-, and 10-year risk of mortality, intestinal obstruction, and use of biologic therapy compared to dulaglutide use. Risks of other short-term outcomes, such as Clostridioides difficile infection, steroid use, and C-reactive protein (CRP) and fecal calprotectin (FCP) levels were not different between the two groups. (P1164)

Josue A. Davila, MD, from Case Western Reserve University/MetroHealth, also conducted a retrospective study using TriNetX data on patients with Crohn’s disease (CD) or ulcerative colitis (UC) who initiated GLP-1 receptor agonist therapy (n=6,844) and a cohort who did not (n=6,844), matched for age, sex, BMI, disease, prior steroid use, and biologic use. GLP-1 receptor agonist use was associated with a reduced risk of IV steroid use, hospitalizations, and emergency department (ED) visits. The benefits of GLP-1 receptor agonist therapy may be related to modification of both metabolic and inflammatory pathways. (P1193)

Fariha Hasan, MD, from Cooper University Hospital, conducted an analysis of the National Inpatient Sample data on 829 hospitalized patients with both diabetes mellitus and IBD, stratified by use of GLP-1 receptor agonists. Patients in the GLP-1 group had a significantly shorter length of stay, fewer IBD-related surgeries, and lower need for corticosteroids. The benefits of GLP-1 receptor agonists was higher in patients who were also obese. (P5358)